Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Dublin, Oct. 20, 2016 -- Research and Markets has announced the addition of the "The Overview of Japanese Pharmaceutical Industry ver2016" report to their offering.
This report talks about the overview of Japanese pharmaceutical industry. By reading this report, readers will understand overall picture about the industry, from various aspects.
Domestic pharmaceutical market size is said to be about 6.9 trillion yen at the ex-manufacturer level, and about 10.8 trillion yen in terms of drug price. While the market size of non-prescription drugs is slightly declining, that of ethical drugs is on the rise, accounting for about 90% of the whole market.
Key Topics Covered:
1. Summary
2. Definition of pharmaceutical industry
3. Classification of pharmaceutical industry
4. Definition of drugs
5. Distribution structure of drugs
6. Pharmaceutical market size in Japan
7. Regulation of related laws
8. Related industry groups
9. High profitability
10. Long history and family management
11. Difficulty of new drug development
12. Structural risk peculiar to the pharmaceutical industry, Patent cliff
13. Disclosure of pipeline
14. Low penetration of vertical integration
15. Changing business environment
16. Companies striving for structural reform
17. Differences between Japanese and foreign companies
18. Characteristics of Labour market
19. Concentration of major companies in member countries of the Organization for Economic Co-operation and Development (OECD)
20. Reference: Comparison with the U.S. and European countries
For more information about this report visit http://www.researchandmarkets.com/research/k4qjk2/the_overview_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals
